Lv21
190 积分 2021-12-09 加入
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
2小时前
求助中
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
2小时前
已完结
Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey
23天前
已完结
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
23天前
已完结
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
2个月前
已完结
When East meets West in clinical trial designs! Reply to “Discussion regarding the establishment of pain- and depression-specific acupoints in a randomized controlled trial with crossover design”
2个月前
已完结
The non-small-cell lung cancer drug market
3个月前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
3个月前
已完结
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
3个月前
已完结
Outcomes and experience of anatomical partial lobectomy
3个月前
已完结
皖公网安备34019202002308
